Worth reading
42Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Who is moving to which position
Resolved 8 September 2026Incoming appointee
2 itemsScheduled Appointment DateScheduled appointment date
Utsumi Osamu (内海 修)
Previous positionDirector, Head of the West Japan Branch
New positionRepresentative Director and President
Hara Chitoshi (原 千年)
Previous positionHead of the Chubu Regional Sales Department, West Japan Branch
New positionExecutive Officer, Head of the Medical Sales Division
Date of birth7 March 1967 (Utsumi Osamu (内海 修))
Year joined the company1989 (Utsumi Osamu (内海 修))
Because the names and counts do not correspond, they are shown as reported without linking the counts to individual names.Departing officer
3 itemsDate of departure30 September 2026
Nagafuku Yasuhiro (長福 恭弘)Next role stated
Former PositionRepresentative Director and Chairman, also Representative Director and Executive Vice President of ㈱メディパルＨＤ
New positionDirector and Corporate Adviser, also Representative Director and Executive Vice President of ㈱メディパルＨＤ, in charge of the pharmaceutical business
Watanabe Shuichi (渡辺 秀一)Next role stated
Former PositionDirector and Corporate Adviser, also Representative Director and President of ㈱メディパルＨＤ, overseeing group compliance
New positionAdviser
Yarisui Hiroshi (鎗水 博司)Stepping down
Former PositionDirector, also Director of ㈱メディパルＨＤ, in charge of financial strategy, and Audit & Supervisory Board Member of 東七㈱
New positionNot disclosed
“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.
Whether the incumbent will remain in office (whether they will retain their position)
Nagafuku Yasuhiro (長福恭弘) will remain on the Board as a Director and Corporate Adviser. After stepping down as Director and Corporate Adviser, Watanabe Shuichi (渡辺秀一) will become a Corporate Adviser. Yarisui Hiroshi (鎗水博司) is Not disclosed.
| Item | Details |
|---|---|
| Resolution date | 8 September 2026 |
| Scheduled Appointment Date | Scheduled appointment date |
| Date of departure | 30 September 2026 |
| Name of appointee | Utsumi Osamu (内海 修), Hara Chitoshi (原 千年) |
| Appointee's new position | Representative Director and President, Executive Officer, Head of the Medical Sales Division |
| Appointee's previous position | Director, Head of the West Japan Branch, Head of the Chubu Regional Sales Department, West Japan Branch |
| Appointee's date of birth | 7 March 1967 (Utsumi Osamu (内海 修)) |
| Year the appointee joined the Company | 1989 (Utsumi Osamu (内海 修)) |
| Name of departing officer | Nagafuku Yasuhiro (長福 恭弘), Watanabe Shuichi (渡辺 秀一), Yarisui Hiroshi (鎗水 博司) |
| Former position of departing officer | Representative Director and Chairman, also Representative Director and Executive Vice President of ㈱メディパルＨＤ, Director and Corporate Adviser, also Representative Director and President of ㈱メディパルＨＤ, overseeing group compliance, Director, also Director of ㈱メディパルＨＤ, in charge of financial strategy, and Audit & Supervisory Board Member of 東七㈱ |
| New position of departing officer | Director and Corporate Adviser, also Representative Director and Executive Vice President of ㈱メディパルＨＤ, in charge of the pharmaceutical business, Adviser, Not disclosed |
| Whether the incumbent will remain in office | Nagafuku Yasuhiro (長福恭弘) will remain on the Board as a Director and Corporate Adviser. After stepping down as Director and Corporate Adviser, Watanabe Shuichi (渡辺秀一) will become a Corporate Adviser. Yarisui Hiroshi (鎗水博司) is Not disclosed. |
Items this document does not state (9)
Number of shares held by the appointeeReason for departureReason for changeReasons for appointmentNumber of directors after the changeFiling as an independent officerDetails of organizational changesChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.No reason for the personnel change was provided.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.